Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162990 | 0.76 | CPA1 (0.49) | KMOCPA1 | |
| SCHEMBL221352 | 0.73 | TDP1 (0.47) | CPA1 | |
| SCHEMBL221353 | 0.73 | TDP1 (0.47) | CPA1 | |
| SCHEMBL22831433 | 0.72 | CPA1 (0.51) | CPA1 | |
| SCHEMBL11779038 | 0.72 | TP53 (0.56) | ANPEPENPEPTP53FBP1CA1 | |
| SCHEMBL11149119 | 0.72 | TDP1 (0.46) | CPA1 | |
| SCHEMBL27997462 | 0.71 | ANPEP (0.68) | ANPEPENPEPGRM4CA1CA2 | |
| SCHEMBL2810142 | 0.71 | ANPEP (0.68) | ANPEPENPEPGRM4CA1CA2 | |
| SCHEMBL3478224 | 0.71 | NPC1 (0.45) | CPA1 | |
| SCHEMBL3462628 | 0.71 | AKR1C3 (0.50) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112280819-A | Application of FRT cell strain in preparation of preparation or kit for screening CaCC regulator | 吉林医药学院 | 2021-01-29 | — | — | CN | disclosed |